Unionized workers of Eastar Jet blamed Jeju Air for the botched merger and acquisition deal due to its "conscienceless and irresponsible" motives.
According to the union, Jet Star intends to monopolize the market by either bankrupting Eastar Jet or asking the government for more subsidies to employ some 1,600 Eastar Jet workers supposedly.
Jeju Air claimed it walked away from a 54.5 billion won merger deal due to Eastar Jet's failure to meet the deadline in fulfilling prerequisites.
The deal culminated in a controversy over issues as corporate restructuring and unpaid wages.
Market observers view the planned merger with Eastar Jet as an attempt by Jeju Air to fortify its position among South Korea's three major airlines, with Korean Air and Asiana Airlines.
Jeju Air and Eastar Jet have a combined 68 aircraft.
The union added that the government neglected the aviation industry's economic situation for three months until it severely deteriorated.


Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 



